Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conflict of interest br Acknowledgments This work was sup
2024-12-13

Conflict of interest Acknowledgments This work was supported by research grant [PR26/20326] from Santander Bank/UCM. The authors would like to thank Miguel Capo, Professor of Toxicology from the Universidad Complutense de Madrid, for his counseling during the preparation of the present work.
-
The use of one or more of psychotropic medications and
2024-12-13

The use of one or more of psychotropic medications and hypnotics was associated with a higher risk of falls in the current study. Previous studies have also shown that these medications increase the risk of falls in the geriatric population.25, 26, 27, 28, 29, 30, 31 Clinicians should weigh the risk
-
Taking together findings from our study
2024-12-13

Taking together findings from our study and that from the literature, we propose a model (to be experimentally confirmed) of possible intracellular mechanism of NA-induced regulation of Na-K ATPase subunit expression (Fig. 8). NA acting on α1-AR modulates the α1- and α3-subunit expressions of Na-K A
-
br Extracellular domain architecture The extracellular regio
2024-12-13

Extracellular domain architecture The extracellular region of GABAB receptor exists in a heterodimeric configuration regardless of interactions within the rest of the protein (Geng et al., 2012, Liu et al., 2004, Nomura et al., 2008). The extracellular domains of the GABAB1 and GABAB2 subunits ar
-
SEN0014196 mg Receptors containing an x y subunit interface
2024-12-13

Receptors containing an αx/γy subunit interface, where x=1, 2, 3, 5 and y=1–3, form a high-affinity binding site for benzodiazepines (Figure 1A), for the later developed Z-drugs of different chemotypes, and for a large number of chemically distinct research compounds 17, 18 (Box 1 for examples). For
-
Rosiglitazone HCl TUNEL assay Apoptotic DNA fragmentation in
2024-12-13

TUNEL assay. Apoptotic DNA fragmentation in Rosiglitazone HCl was measured using a commercially available TUNEL assay kit (Thermo Fisher). Frozen cells were fixed with 10% paraformaldehyde/PBS. Apoptosis was determined by staining the 3′-OH ends of fragmented DNA with biotin-dNTP using DNA I klenow
-
To further address the mechanism of Didox s suppressive effe
2024-12-13

To further address the mechanism of Didox’s suppressive effects on mast cell activation, FceRI receptor MK 571 and downstream transcription factor induction were assessed. We found that Didox had no effect on FceRI surface expression, and thus concluded that Didox effects must be occurring downstre
-
Enhancers are short regions of DNA that are bound by
2024-12-13

Enhancers are short regions of DNA that are bound by DNA-binding proteins (TFs) to increase the likelihood of a particular gene to be expressed. Importantly, enhancers can be identified, and classified, by their patterns of chromatin accessibility and of enrichment in certain histone modifications.
-
Most human diseases e g cancer diabetes and neurodegenerativ
2024-12-13

Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te
-
While there is much in
2024-12-13

While there is much in vivo work on prion-like Aβ, it has not been shown that one can induce inclusions of Aβ in cultured cells as has been shown for tau and α-synuclein. One reason is practical; Aβ is a low molecular weight metabolite cleaved from within the larger amyloid precursor protein (APP) a
-
br Materials and methods br Results br
2024-12-12

Materials and methods Results Discussion Endophilin A1 is a membrane-binding protein that is mainly distributed in the central nervous system (Giachino et al., 1997), localizes in the dendritic shafts and spines of mature neurons (Yang et al., 2015), and relates to the function and morpholo
-
br Effects of BCAAs on glucose
2024-12-12

Effects of BCAAs on glucose metabolism Insulin plays an exclusive role in regulation of glucose metabolism, and obesity and type 2 diabetes induce hyperinsulinemia due to insulin resistance. Plasma BCAA concentrations are increased by 14–20% in patients with hyperinsulinemia under overnight fasti
-
In the late s Solvay Pharmaceuticals discontinued the Phase
2024-12-12

In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
-
Although ACE genetic variance does not influence
2024-12-12

Although ACE genetic variance does not influence the level of bradykinin significantly, the bradykinin level tends to be affected by ACE inhibitor therapy used by patients. ACE inhibitor reduces the ACE activity that may lead to the accumulation of serum bradykinin. The level of bradykinin tends to
-
br Acknowledgments This work was supported by a
2024-12-12

Acknowledgments This work was supported by a grant of the Romanian National Authority for Scientific Research, CNCS – UEFISCDI, project no. PN-II-ID-PCE-2011-3-0571, awarded to F.A.M. D.V.N. was co-financed from the European Social Fund through Sectorial Operational Program Human Resources Develo
16017 records 48/1068 page Previous Next First page 上5页 4647484950 下5页 Last page